Background: Evidence about the use of dolutegravir (DTG) and rilpivirine (RPV) as an antiretroviral therapy (ART) in treatment-experienced patients is scarce. Objective: To explore the effectiveness, safety, and costs of switching to a DTG plus RPV regimen in this population. Methods: This observational, prospective study included all treatment-experienced patients who switched to DTG plus RPV between November 2014 and July 2016. Patients were excluded if resistance mutations to integrase inhibitors or RPV were found. The effectiveness endpoint was the proportion of patients who achieved virological suppression (viral load [VL] <50 copies/mL) at week 48 (W48). Safety (incidence of adverse events leading to discontinuation and laboratory abnormalities), adherence, and costs were analyzed. Results: A total of 35 patients were included, and 91.4% were virologically suppressed at baseline. Patients were treated with ART for a median of 14 years (interquartile range = 7-20). At W48, 91.4% of patients were virologically suppressed (95% CI = 77.0-98.2). Two of the 3 patients not suppressed at baseline achieved undetectable VL at W48, and 2 patients discontinued DTG plus RPV (intolerance and a drug-drug interaction). None of the virologically suppressed patients at baseline showed virological rebound through W48. There were no significant changes in lipid, liver, and renal profiles. The proportion of patients with an ART adherence >90% increased from 65.6% to 93.8% (P = 0.004). The annual per-patient ART costs dropped by €665 (P = 0.265). Conclusions: Switching to DTG plus RPV seems to be an effective and safe strategy. Significant improvements in patients' adherence and costs were achieved.
Introduction
Access to antiretroviral therapy (ART) has greatly reduced morbidity and mortality in HIV patients, transforming the prognosis from a life-threatening disease to a chronic condition that requires lifelong management. 1 In Spain, the proportion of HIV patients 50 years and older has increased from 7.7% in 2000 to 41.5% in 2015. 2 The growth in the number of elderly HIV-infected patients arises as a medical challenge because of the high proportion of widely treatment-experienced individuals with comorbidities. 3 In addition, long-term exposure to antiretroviral (ARV) drugs increases the likelihood of developing resistance mutations in cases of poor adherence, which may limit the use of certain classes of ARV.
This situation has highlighted the interest in simplified regimens to minimize cumulative drug exposure, reduce impact on comorbidities, and improve tolerability and adherence. Dolutegravir (DTG) is an integrase inhibitor (INI) with a high resistance barrier, and rilpivirine (RPV) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) considered a metabolic-friendly ARV drug. Despite the good results with triple-drug regimens available, the outcomes of monotherapy with DTG have been discouraging so far. 4 The administration of RPV plus DTG has been studied showing an in vitro synergistic effect in viral suppression and no significant pharmacokinetic interactions between the 2 drugs in healthy individuals. 5, 6 Therefore, dual therapy with DTG 50 mg plus RPV 25 mg, both once daily, has emerged as an attractive option with expected high antiretroviral activity, good tolerability, and an improved metabolic profile. Two ongoing phase III randomized clinical trials are assessing the efficacy and safety of DTG plus RPV in virologically suppressed patients with no history of virological failure (SWORD-1 and SWORD-2). 7, 8 One real-world experience has been reported so far, which showed that 49/50 patients (86% were virologically suppressed at baseline) followed up to 48 weeks achieved virological suppression after switching. 9 Given the lack of data on the efficacy and safety of DTG plus RPV, this regimen is not specifically mentioned in current guidelines. 10, 11 Although the management of treatmentexperienced patients has been addressed in these guidelines, limited treatment guidance is provided because of the lack of evidence from clinical trials. An optimal combination therapy usually comprises 2 or 3 fully active agents based on patients' characteristics and previous treatments.
The aim of this study was to provide more data on the effectiveness of DTG plus RPV in treatment-experienced HIV-1 infected patients switching to DTG plus RPV, regardless of their previous ART. Safety of the new ART, adherence, and the economic impact of the switching were also evaluated.
Methods

Study Design and Population
A prospective observational study was carried out on adult outpatients switching to DTG plus RPV dual therapy between November 2014 and July 2016 in a tertiary hospital in Madrid, Spain. The study sample comprised all consecutive adult treatment-experienced patients who initiated this dual therapy, regardless of previous regimens. Patients were excluded if resistance to any INI or RPV was shown or if they were pregnant. All patients were followed until they completed 48 weeks of treatment or discontinued.
Assessments
The primary end point was to assess DTG plus RPV effectiveness, defined as the proportion of patients who achieved virological suppression (viral load [VL] <50 copies/mL) at week 48 (W48) by intention-to-treat analysis. Patients who discontinued the DTG plus RPV regimen for any reason prior to W48 as well as those with a VL >50 copies/mL (detectable VL) at W48 were considered virological failures. The secondary end points were safety (incidence of adverse events leading to discontinuation and impact of this ART on laboratory values), adherence to ART, and the economic impact of the switch (measured as the difference of the annual per-patient ART costs between DTG plus RPV and the previous ART).
Demographic and clinical characteristics, including VL, CD4+ T-cell count, and CD4/CD8 ratio, were recorded. The fasting lipid profile, liver enzymes, total bilirubin, creatinine, and glomerular filtration rate (GFR) estimated by applying the Modification of Diet in Renal Disease (MDRD) equation were also monitored throughout the study period and compared at baseline and at W48. 12 In the case of GFR <60 mL/min, blood urea nitrogen, urine microalbumin-tocreatinine ratio, and urine protein-to-creatinine ratio were also analyzed. Other variables such as concomitant medications, the reason for change to DTG plus RPV and reason leading to discontinuation of the dual therapy, the previous pill burden and adherence to the ARTs, and the annual perpatient ART costs were recorded. Plasma HIV-1 RNA (VL) was determined using the SIEMENS VERSANT HIV-1/ kPCR system (limit of quantification: 37 HIV-1 RNA copies/mL). Reverse-transcriptase, protease, and integrase sequencing were performed prior to the change following manufacturer's indications. Drug resistance mutations as well as genotypic resistance (resistance or possible resistance) were defined according to the Stanford HIV Drug Resistance Database algorithm. Adherence was measured using the method of medication possession ratio, which was reported automatically by the electronic dispensing software of the pharmacy department. This method uses 3 elements: (1) the quantity dispensed in each visit by the pharmacy department; (2) the prescribed daily dosage, or the amount of medication to be consumed per day, which is calculated as pills per day; and (3) the number of days' supply, that is, the quantity dispensed divided by the prescribed daily dosage. The medication possession ratio was calculated by dividing the sum of a day's supply by the number of days in period multiplied by 100. Adherence was compared 1 year before switching and from switching until W48 or until DTG plus RPV was discontinued for any reason. Pill burden was calculated as the total number of pills the patient took on a daily basis. ART costs were calculated based on the actual dose administered and the drug acquisition costs for each year. These prices may differ from officially established ones.
Statistical Analysis
Continuous variables were described by medians and interquartile ranges (IQRs) and categorical variables by frequencies and percentages. The Wilcoxon signed-rank test was used for comparisons between 2 continuous variables. The McNemar-Bowker test was used to compare 2 categorical variables. A P value <0.05 was considered statistically significant. Computer support used for the statistical analysis was IBM SPSS Statistics 19 (SPSS Inc, Chicago, IL).
Ethical Aspects
This research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. The study was approved by the Pharmacy and Infectious Diseases Committees and by the Antimicrobial Subcommittee.
Results
Baseline Characteristics
We identified 35 patients who switched from their conventional ART to DTG plus RPV. Prior to the switch, 32 (91.4%) had undetectable VLs, and 3 patients (8.6%) showed VLs of 72, 39 690, and 91 660 copies/mL. Baseline characteristics, previous ART, and the reasons for switching to this dual therapy are summarized in Table 1 . The median age was 49 years (IQR = 46-53), and 62.9% of patients were male. Coinfection with hepatitis C virus (HCV) was present in 54.3% of cases, and 28.6% of patients were treated with direct-acting antivirals during the study. The baseline median CD4+ T-cell count was 606 cells/mm 3 The most frequent combination of NRTI was emtricitabine/ tenofovir disoproxil (FTC/TDF, 31.4%), and the third drug was mainly ritonavir-boosted darunavir (54.3%), followed by raltegravir (31.4%). Only 4 patients were treated with a single tablet regimen before the switch. Resistance mutations were confirmed in 13 patients (37.1%), with a median of 4 mutations (IQR = 1-9) per patient; 19 patients (54.3%) never had a genotype for historical reasons. Overall, 14.3% of patients carried HIVresistant strains to 3 ARV classes and 11.4% to 2 classes. Also, 11 patients (31.4%) had PI resistance mutations, of whom 10 also had resistances to other classes (Table 2) . No RPV or INI resistance mutations were found in any patient at the time of the switch.
A total of 16 (45.7%) patients switched to the dual therapy because of adverse events with current ART, including 6 patients with dyslipidemia (mostly darunavir treated, n = 5), 4 patients with decreased bone density (mostly TDF treated, n = 3), 2 patients with renal toxicity, and 4 patients with other toxicities (Table 1 ). Eight patients (22.9%) switched because of drug-drug interactions, including 5 patients who were treated with direct-acting antivirals for the HCV infection. In 3 (8.6%) cases, DTG plus RPV was used as a salvage therapy for patients showing virological failure, and optimization of the genetic barrier was recorded as the cause for the switch in 4 (11.4%) other patients. . Two patients discontinued dual therapy early. Intolerance and interaction between RPV and omeprazole were recorded as the reasons for discontinuation. Virological suppression in these 2 patients was maintained by different dual-therapy regimens according to clinicians' criteria. Therefore, none of the virologically suppressed patients at baseline experienced virological rebound through W48. When these 2 patients are excluded from the analysis, the proportion of suppressed patients who maintained undetectable VL at W48 was 30/30 (100%; 95% CI = 88.4-100.0). Among the 3 patients who were not suppressed at baseline, 2 achieved viral suppression at W4 after switching, and it was maintained at W48. The other patient, who presented a VL of 91 660 copies/mL at baseline, did not achieve viral suppression during the study period, but VL decreased to 260 copies/mL at W48. This patient had confirmed NRTI (M41L, T215Y) and PI (L10I, I13V, K20R, D30N, M36I, N88D) resistance mutations at baseline and poor adherence to ART. Overall, median CD4+ T-cell count was 606 cells/mm 3 (IQR = 432-858) at baseline and 611.5 cells/mm 3 (IQR = 380-872) at W48 (P = 0.868).
Safety
Two patients discontinued DTG plus RPV during the follow-up period: one because of intolerance with general malaise, insomnia, and joint pain and the other because of an interaction between RPV and omeprazole. This patient had a diagnosis of chronic gastritis and was being treated with ranitidine. However, the lack of clinical control of the symptoms required ranitidine to be substituted with omeprazole, which in turn led the dual therapy with DTG plus RPV to be suspended.
The impact of DTG plus RPV in laboratory parameters at W48 is shown in Figure 1 . No nonstatistical differences for any lipid parameter were found. In patients previously treated with PI, the median decreases observed in total cholesterol, low-density lipoprotein cholesterol, total triglycerides, and atherogenic index of plasma at W48 were 9.0, −2.5, 28.0, and 0.1 mg/dL, respectively (P = 0.956; P = 0.340; P = 0.152; P = 0.881). The analysis of the subgroup of patients who switched to DTG plus RPV because of dyslipidemia (n = 6) showed median decreases in total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and total triglycerides at W48 of 21.0, −8.0, 1, and 85.5 mg/dL, respectively (P = 0.116; P = 1.000; P = 0.223; P = 0.345). Regarding liver function tests, the median reduction in γ-glutamyl transferase (GGT) and alkaline phosphatase (AlkPhos) was significant (7.5 and 1.0 IU/L; P = 0.001, P = 0.005, respectively; Figure 1 ). However, no significant changes were observed in ALT, AST, and total bilirubin levels. When the subgroup of patients who were treated with direct-acting antivirals for the HCV were excluded from the analysis, the median reduction in GGT and AlkPhos remained significant (6 and 11 UI/L; P = 0.007, P = 0.024, respectively).
Median GFR decreased from 91.0 to 84.1 at W48 (P = 0.022). Overall, 44.1% of patients at baseline and 67.7% of patients at W48 had a GFR <90 mL/min/1.73 m 2 . However, no increase in the number of patients showing a GFR <60 mL/min/1.73 m 2 was recorded (6 patients [17.1%] at baseline vs 5 patients [14.3%] at W48), and other renal function parameters (blood urea nitrogen, urine microalbumin to creatinine ratio, and urine protein to creatinine ratio) were within the normal range in all cases. The analysis of patients who were not previously treated with TDF at baseline (24 patients) showed a trend toward a decrease in GFR at W48 with a median of 5.7 mL/min/1.73 m 2 (IQR = −0.7 to 14.4; P = 0.055). In the subgroup of patients who switched from an ART that included TDF (11 patients), the median decrease was 7.0 mL/min/1.73 m 2 (IQR = 1.4-19.1; P = 0.260); in patients who switched from TDF + PI/r (4 patients), the median decrease was 6.5 mL/min/1.73 m 2 (IQR = 2.0-16.6; P = 0.068).
ART Adherence and Pill Burden
The median adherence in the year prior to the switch to DTG plus RPV was 94.0% (IQR = 89.5-99.0), and the median adherence throughout the study period was 99.0% (IQR = 96.7-99.0; P < 0.001). Whereas an adherence to ART >90% was recorded in 65.6% of patients before the switch, this percentage increased to 93.8% (P = 0.004) after the switch. In the subgroup of patients whose previous ART was based on ≥4 pills per day (n = 14), the proportion of patients with adherence >90% improved from 57.1% to 100%. In the subgroup of patients whose previous ART was based on 3 pills per day (n = 14), this proportion increased from 64.3% to 85.7%. In the subgroup of patients whose previous ART was based on a twice-daily schedule (n = 14), the proportion of patients with adherence >90% improved from 71.4% to 92.9%.
Cost Analysis
The median annual per-patient ART costs before switching was €8358 (IQR = 7223-9719) and €7693 after switching to DTG plus RPV. A median of €665 (IQR = −470 to 2025; P= 0.265) of cost savings was calculated. The greatest cost reductions were obtained in the subgroups of patients previously treated with INI-based combinations and in patients who were taking 3 or more drugs before switching: €1886 (IQR = −452 to 3378; P = 0.096) and €1455 (IQR = −451 to 2026; P = 0.029), respectively.
Discussion
Our study explored the real-life effectiveness and safety of DTG plus RPV dual therapy in a small cohort of treatmentexperienced HIV patients. To our knowledge, this is the second experiment reported and the first evaluating the impact of this switch on adherence to ART and costs. After 48 weeks of follow-up, 91.4% of patients showed viral suppression, with 2 of the 3 previously nonsuppressed patients achieving undetectable VL. These results suggest that the high genetic barrier and different resistance profile of this drug combination can be a suitable option for heavily treatment-experienced patients, including those with multiple resistance mutations. 
Abbreviations: NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. a Percentages are expressed from the total number of patients with mutations (n = 16). Detailed information for mutations that are only present in 1 patient are not shown.
The effectiveness of DTG plus RPV dual therapy is being investigated in 2 phase III clinical trials, which include virologically suppressed patients switching from a 3-or 4-drug regimen (INI, NNRTI, or boosted PI based) ART (SWORD-1 and SWORD-2). 7, 8 Regarding real-world data, there is only 1 cohort reported in the literature that shows similar results to those found in this study. Capetti et al 9 evaluated the effectiveness and safety of DTG plus RPV for 24 weeks in a cohort of 132 patients in 8 Italian centers (88% virologically suppressed). At W24, 1 patient had viral rebound without resistance mutations as a result of missed drug refill, 19 had 1 to 49 copies/mL, and in 112 patients, no VL was detected. At W48, 1 patient out of 50 had discontinued the treatment, 4 had 1 to 49 copies/mL, and in 45, no VL was detected. Although not focused on evaluating the effectiveness of the DTG plus RPV combination, Gubavu et al 14 reported results from a small cohort of 31 patients on several DTG-based dual regimens (81% virologically suppressed), in which 11 patients received DTG plus RPV. After a median of 50 weeks of follow-up, only 1/31 patients had a detectable VL, but separate data for different regimens were not given.
In regard to the safety profile, we identified a discontinuation rate of 5.7% at W48. This rate is slightly higher than the results provided by Capetti et al 9 , who reported 1.5% (2/132) of interruptions for safety at W24 (1 because of headache and 1 because of drug-drug interaction between RPV and a proton pump inhibitor) and none in the subgroup of 50 patients who were followed up to 48 weeks. Data from other cohorts have suggested that DTG is associated with a higher incidence of neuropsychiatric side effects (insomnia, dizziness, headache, depression) compared with that reported in clinical trials. Specifically, the studies of Borghetti et al, 15 Hoffmann et al, 16 and De Boer et al 17 reported rates of discontinuation for neuropsychiatric adverse events between 3.4% and 6%. However, this did not hold true within our study because only 1 of the 32 patients (3.1%) who were not previously treated with DTG discontinued the therapy for this reason. A possible association between neuropsychiatric side effects and abacavir administration, age more than 60 years, female sex, and a higher body mass index has been described, but more studies are needed to determine their incidence and causal mechanism. Regarding laboratory data, there were no significant changes in lipid profile. Liver function profile improved slightly after switching to DTG plus RPV in the overall population, although only GGT and AlkPhos decreased significantly. A significant decrease in the estimated GFR was found at W48 (6.5 mL/min/1.73 m 2 by MDRD), but there was no increase in the proportion of patients showing a GFR <60 mL/min/1.73 m 2 . DTG and RPV inhibit the organic cation transporter 2 (OCT2), which affects active tubular secretion of creatinine, increasing its blood levels and producing a "false" decrease of the estimated GFR. 12 In fact, other parameters of renal function such as blood urea nitrogen, urine microalbumin to Abbreviations: Alk Phos, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Bi, total bilirubin, GFR, glomerular filtration rate; GGT, γ-glutamyl transferase; HDL, highdensity lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; TG, triglycerides.
creatinine ratio, and urine protein to creatinine ratio remained within the normal range throughout the study period.
In terms of patient adherence to ART, this study shows an enhancement after switching to DTG plus RPV in the subgroups of patients whose previous ART was based on ≥3 pills per day or whose previous ART was based on a twicedaily schedule. These results make this combination an attractive alternative, both to reduce pill burden and improve adherence in heavily treatment-experienced patients. Lower pill burden has demonstrated higher adherence rates and better virological outcomes in several randomized controlled trials and clinical cohort studies. [18] [19] [20] In accordance with our results, these studies show that patients taking once-daily regimens have higher adherence rates than those taking twice-daily dosing regimens. However, data to support or refute the superiority of fixed-dose combination products (1 pill) versus 3 pills of individual drugs in oncedaily regimens are still limited. 11 In a cohort of 7073 insured HIV patients in the United States, patients receiving a single pill per day were significantly more likely to reach a 95% adherence threshold versus patients receiving 3 or more pills per day (odds ratio = 1.59; P < 0.001). However, one of the limitations of this retrospective study was that it was not possible to determine the daily dosing frequency over which those pills were distributed (eg, twice daily, thrice daily). 21 Finally, cost analysis is particularly important in HIV given the recommendations for immediate initiation of lifelong treatment, the increasing number of patients taking ART, and the high cost of these regimens. This study revealed that switching to DTG plus RPV reduced the treatment cost in comparison to the previous ART in the study population. The median annual cost per patient reduction of €665 came mainly from the lower acquisition cost of the dual therapy compared with the previous, more complex regimens. However, the forthcoming patent expiration of the backbone drug combination FTC/TDF and the availability of the generic version of abacavir/lamivudine (ABC/3TC) are expected to reduce the reported saving margins. In any case, it should be noted that if DTG plus RPV is used in other scenarios, such as first-line treatment or as an earlier switching strategy, it may not result in cost savings because lower pill burden is not always synonymous with lower cost. For example, from the Spanish public health system perspective, the standard triple therapy with FTC/TDF plus efavirenz or ABC/3TC/DTG is cheaper than DTG plus RPV (€6925 vs €7373 vs €7693; laboratory-notified prices, including taxes). 22 Our results suggest that DTG plus RPV can be considered a valid strategy for treatment-experienced patients showing drug-related toxicities or poor adherence with no resistance to either ARV drug. However, other simplification strategies are also emerging that will expand the therapeutic options for these patients. Different approaches to reducing drug exposure and increasing patient adherence to medication are being tested. The ongoing phase IIb LATTE-2 trial is studying the combination of cabotegravir (a new INI) and RPV formulated into long-acting nanosuspensions for monthly intramuscular administrations. 23 The main limitation of our study is the small size of the cohort resulting from the exceptional use of this regimen because it is not yet recommended by guidelines. Second, the evaluation of ART tolerability after switching is limited by the nonrandomized nature of this study. Third, the adherence was determined using dispensing data records, and it was assumed that all medications were used as directed. Fourth, regarding cost analysis, it should be taken into account that drug prices may differ between countries and their nationally established prices owing to discounts negotiated with drug suppliers. Finally, the future use of DTG plus RPV could be influenced by other simplified regimens such as DTG plus lamivudine, which is currently being studied in treatmentnaïve patients in 2 clinical trials (GEMINI-1 and GEMINI-2). 24, 25 If promising results are subsequently confirmed, the good tolerance of lamivudine, its significantly lower acquisition cost, and fewer drug-drug interactions compared with RPV would make it a highly attractive option.
Conclusion
In this study, no cases of virological failure were observed among virologically suppressed patients who adhered to the DTG plus RPV regimen. Switching to this simpler regimen seems an effective and safe strategy for treatment-experienced patients having important comorbidities or predisposition to toxicity, who need metabolic-friendly drugs and/or have adherence difficulties. However, more studies are needed to investigate its long-term durability and effectiveness in patients experiencing failure of ART. Before switching, a careful analysis of previous ARTs and a genotypic resistance evaluation should be performed. Combining that with regular adherence assessment and counseling during treatment will contribute greatly to the success of dual therapy.
